Ovid Therapeutics Inc. announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies. The company reports that the first patient has been randomized to receive either OV935 or placebo in the ELEKTRA trial, and that patient screening is underway for the ARCADE trial.
September 24, 2018
December 2, 2019
Three Anti-Seizure Drugs Equally Effective for Severe Form of Epilepsy
New findings published in the New England Journal of Medicine reveal that the three drugs, levetiracetam, fosphenytoin, and valproate, are equally safe and effective in treating patients with refractory status epilepticus.